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The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limi-
tations affecting reproducibility and there is no consensus on the role of new markers. The aim of this
project was to identify reproducible criteria and consensus on markers recommended for the diagnosis
of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as “required” or “recommended” for
CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to
validate “required” markers using normal peripheral blood was developed. Responses were received
from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5–20 in
82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for “required” diagnostic
markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. “Recommended” markers potentially
useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible crite-
ria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and
showed >97% concordance with current approaches. A pilot study to validate staining quality was com-
pleted in 11 centers. Markers considered as “required” for the diagnosis of CLL by the participants in
this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria
and practice. Importantly, a reproducible approach to validate and apply these markers in individual lab-
oratories has been identified. Finally, a consensus “recommended” panel of markers to refine diagnosis
in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be pro-
spectively evaluated. VC 2017 International Clinical Cytometry Society
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BACKGROUND
The WHO, IWCLL, and NCCN diagnostic criteria for
CLL is based on the morphology and immunophenotype
of the neoplastic B-cells with co-expression of CD19,
CD5, CD23, with weak CD20 and monoclonal surface
immunoglobulin (sIg) expression (1–3). Although there
are several recurrent molecular abnormalities present in
CLL, none is specific for CLL (4) and therefore immuno-
phenotyping still plays a central role in the diagnosis of
CLL.
The current diagnostic criteria have some limitations
affecting reproducibility, in particular relating to flexibil-
ity in the requirement for each marker to be present or
absent as well as in the required expression level of
each marker. The WHO definition states that CLL/SLL
cells “usually co-express CD5 and CD23” and that “using
flow cytometry, the tumor cells express dim surface
IgM/IgD, CD20, CD22, CD5, CD19, CD79a, CD23,
CD43, and CD11c (weak). CD10 is negative and FMC7
and CD79b are usually negative or weakly expressed in
typical CLL. It is also considered that “some cases may
have an atypical immunophenotype (e.g. CD5- or CD23-,
FMC71 or CD11c1, strong sIg, or CD79b1)” (1). In
turn, the current IWCLL guidelines also permit variation
in markers expression levels: “CLL cells co-express the
T-cell antigen CD5 and B-cell surface antigens CD19,
CD20, and CD23. The levels of sIg, CD20, and CD79b
are characteristically low compared with those found on
normal B cells. Each clone of leukemia cells is restricted
to expression of either kappa or lambda immunoglobu-
lin light chains. Variations of the intensity of expression
of these markers may exist and do not prevent inclusion
of a patient in clinical trials for CLL” (2).
Although some degree of flexibility is required to
ensure that CLL diagnostic criteria are widely applicable,
this can pose problems to the reproducibility of diagnos-
tic criteria, particular if a scoring system that may per-
mit absence of either CD5 or CD23 is employed (5,6).
In addition, several markers such as CD200 (7,8) and
ROR1 (9–12) may contribute to the diagnosis of CLL
and related disorders. However, there is no consensus
yet on how such markers should be incorporated into
diagnostic algorithms. Moreover, although the addition
of new markers to established diagnostic panels may
improve diagnostic precision, this would require a sys-
tematic and well-designed approach.
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The primary aim of this project was to achieve con-
sensus on the minimum set of markers required for the
diagnosis of CLL and develop a reproducible approach
to validate and apply these markers in different laborato-
ries. A secondary aim was to identify additional markers
deserving prospective evaluation.
METHODS
Identification of Consensus on Required
and Recommended Marker Panels
ERIC/ESCCA members were invited to participate in a
survey to classify 35 potential flow cytometry markers
as being “required,” “recommended,” “suggested,”
“uninformative,” or “not sure” for the diagnosis of CLL.
The full survey is shown in Supporting Information.
Results from respondents indicating that they did not
work in a diagnostic laboratory or hospital clinic setting,
or who indicated that their institution did not perform
flow cytometry in the diagnosis or monitoring of CLL
were excluded from analysis. The 35 markers were
selected based on the inclusion in the diagnostic panels
reported in the WHO classification (1), IWCLL guide-
lines (2), Euroflow B-cell panel (8), or if a pubmed
search for “differential diagnosis chronic lymphocytic
leukemia CD” identified a reagent in publications by
two or more different groups (Fig. 1). Consensus for a
marker to be required for CLL diagnosis needed >75%
of participants indicating that the marker was
required, while a marker was put forward to review
if 50% of participants considered the marker to be
“recommended” or “required.” Positive and negative
control populations in normal peripheral blood and the
relative signals required for acceptable markers were
derived from the previous ERIC project for optimizing
CLL MRD (13) or defined through literature search and
review by participants.
The definition of “weak” expression requires a thresh-
old that is reproducibly lower than normal expression
i.e. lower than acceptable variation due to assay impreci-
sion or due to changes associated with sample stability.
The ICCS/ICSH guidelines for validation of cell-based
fluorescence assays (14) recommend assay imprecision
ideally below 10% CV (although this may be higher in
some settings) while specimen stability is determined by
identifying the latest time point at which repeat testing
of 5 samples shows up to 20% change from baseline.
Therefore, difference in fluorescence intensity of <20%
may not be reliably determined, so weak expression was
defined as a median fluorescence intensity at least 20%
lower than the median expression level by normal
peripheral blood B-cells. As laboratories use different
reagents, instrumentation and procedures, each labora-
tory was requested to determine their own reference
range to be used for definition of weak expression.
Consensus for the proposed diagnostic panel specifi-
cation was reached by approval of all participating
authors followed by presentation of the proposal at
ERIC and ESCCA meetings and open consultation on the
final document distributed to all ERIC and ESCCA mem-
bers three months prior to submission.
Retrospective Evaluation
Survey participants were requested to retrospectively
assess the proposed criteria based on the required
markers (Table 1) by providing the number of: total B-
LPD cases evaluated; CD51 B-LPD cases; cases meeting
the proposed criteria and diagnosed as CLL; cases not
meeting the proposed criteria and diagnosed with
another B-LPD e.g. mantle cell lymphoma; cases not
meeting the proposed criteria and diagnosed with CLL;
cases not meeting the proposed criteria with insufficient
material to make a final diagnosis or reported to be
unclassifiable based on available data.
Assessing Reagent/Instrument Quality
A gating strategy to identify the expression levels of
component markers on normal peripheral blood lym-
phocytes was developed (Fig. 2). Participants providing
FIG. 1. The percentage of participants ranking each marker as
required or recommended for evaluation in the diagnosis of CLL. [Color
figure can be viewed at wileyonlinelibrary.com]
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retrospective evaluation were requested to assess the
gating strategy on 10 cases in which the B-cells were
polyclonal. The median fluorescence intensity for the
relevant markers on defined positive and negative con-
trol populations were recorded by 11 different laborato-
ries and returned for central analysis where the relative
fluorescence intensity signal value was calculated. A bor-
derline results was defined as 1–3/10 cases below the
minimum acceptable relative signal target value. A sub-
optimal results was defined as >3/10 cases below the
minimum relative signal target value.
RESULTS AND DISCUSSION
Identifying Consensus on the Markers Required or
Recommended for the Diagnosis of CLL
ERIC/ESCCA members were invited to identify
markers that are “required” or “recommended” for the
diagnosis of CLL from a potential panel of 35 markers.
Responses were received from 154 members of which
150/154 were involved in CLL diagnosis (100 were diag-
nostic laboratory staff, 14 were clinicians and 36 were
involved in both the laboratory and clinical diagnostic
process). Responses from individuals not involved in
CLL diagnosis were excluded from further analysis. The
diagnostic workload was >20 cases per week in 23/150
(15.3%), 5–20 in 82/150 (54.7%), and <5 cases per
week in 45/150 (30%). The survey participant consen-
sus was that the minimum diagnostic panel should
include: CD19, CD5, CD20, CD23, Kappa, and Lambda
(i.e. “required”). Survey participants recommended that
the following markers may also be of value CD22,
CD38, CD45, FMC7, CD79b, CD10, CD43, and CD200.
The complete list of markers and participant responses
are shown in Figure 1.
The minimum required diagnostic panel was put for-
ward for identification of component marker specifica-
tion that could be used to assess reagent and laboratory
quality (see below). The recommended marker panel
was reviewed by the steering committee (AR, PH, MH,
PG, and EM) and it was proposed that the application of
CD22, CD38, CD45, and FMC7 is left to the individual
laboratory preference (i.e. “not recommended”) because
of a variety of reasons. In detail: FMC7 is an epitope of
CD20 (15), the inclusion of both markers being redun-
dant (8); similarly the level of CD22 expression is
closely correlated with CD20 (13); CD45 is used for
identification of leukocyte subsets and provides a back-
bone to many gating strategies but is not essential to
identify CLL cells (8); CD38 is heterogeneously
expressed in CLL (16–18) difficult to standardize (19)
and it is also difficult to identify control populations
with stable expression levels; therefore it was proposed
that the application of CD38 in diagnosis and prognosis
is determined by individual laboratories.
The markers sIgM, CD81, CD103, CD49d, CD11c,
IgD, IgG, and CD25 were recommended by 20–40% of
Table 1
Required and Recommended Markers for Use in the Diagnosis of CLL with Reagent Specification Based on Expression Patterns in
Normal Peripheral Blood.
Control population in normal
peripheral blood
Minimum relative
fluorescence intensity
of positive and
negative control
Inclusion in
diagnostic panel Antigen
Expression in CLL
(% pos vs. control) Positive Negative
populations
(preferred)
Required CD19 Positive (>95%) CD201 B-cells CD31 T-cells 10a
CD5 Positive (>20%) CD31 T-cells CD191 B-cells 30 (65)
CD23 Positive (>20%) CD231 B-cells T-cells 5a
CD20 Weak CD191 B-cells CD31 T-cells 10 (20)
Igj Igk Weak & restricted CD201 B-cells CD31 T-cells 5a
Recommended CD43 Positive (>20%) CD31 T-cells CD201 B-cells 15 (40)
CD79b Weak CD201 B-cells CD31 T-cells 15 (30)
CD81 Weak CD31 T-cells Granulocytes 12 (20)
CD200 Positive (>20%) CD191 B-cells CD31 T-cells 5a
CD10 Negative (<20%) Granulocytes T-cells 10a
ROR1 Positive (>20%) B-progenitors T-cells 5a
Required, consensus from >75% of participants. Recommended, consensus from >50% of participants with the following
exceptions determined by the steering committee and confirmed by further consensus: exclusion of FMC7 (epitope of CD20) (15),
CD38 & CD45 (used for prognostic information and gating orientation but not specifically required for diagnosis), and inclusion of
ROR1 which is closely associated with CLL (9,10) but diagnostic antibodies were not widely available at the time of the survey.
Definition of weak: median fluorescence intensity at least 20% [identified as the minimum measurable difference based on
ICSH/ISLH guideline recommendations for acceptable variation due to assay imprecision and specimen stability (14)] lower than
the median expression level by normal peripheral blood B-cells. Each laboratory was requested to determine their own reference
range.
aSpecifically validated otherwise consensus, defined as approval of all contributing authors with no disagreement on open consul-
tation by ERIC/ESCCA members. Values refer to the relative signal on positive versus negative control populations required to
achieve optimal separation of CLL cells from normal B-cells (13).
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participants and therefore their application is best deter-
mined by individual laboratories with the exception of
CD81 which has been extensively validated in detection
of MRD (13,20,21), therefore understanding the expres-
sion profile prior to treatment may be informative for
differential diagnosis. ROR1 was not on the initial survey
because at the time of preparation there was limited
access to commercial reagents. ROR1 was initially identi-
fied by gene expression profiling studies as a CLL-
specific marker and the role of protein expression in
diagnosis and prognosis has been analyzed in several dif-
ferent studies (9–12) and may be particularly informative
in the discrimination between CLL and CD51 post-
germinal center B-cell disorders (22). Based on all these
considerations, the markers recommended for additional
analysis were: CD43, CD79b, CD81, CD200, CD10, &
ROR1.
For each marker in the required and recommended
panels, a positive and negative control population that
could be readily recognized in normal peripheral blood
was identified, with the exception of ROR1 for which B-
progenitors in the bone marrow are the only normal
positive control. A minimum and recommended relative
signal was also determined either by consensus or by
using data from the CLL MRD project which identified
the relative signal on positive versus negative control
populations required to achieve optimal separation of
CLL cells from normal B-cells (13). The required and rec-
ommended markers with relevant positive and control
populations and expected relative signals are shown in
Table 1. This information was distributed to all ERIC and
ESCCA members for consultation in order to confirm
consensus.
Retrospective Application of the Minimum Required Panel
Using the Proposed Specification
Survey participants involved in the diagnosis of CLL
were requested to retrospectively assess the proposed
criteria shown in Table 1, and 13/150 responded with
the results shown in Table 2. The required criteria were
assessed retrospectively in 14,643 cases referred for
diagnosis of a potential B-LPD, of which 11,721 were
diagnosed with a CD51 B-LPD. Central laboratories for
clinical trials identified cases which had been submitted
for a CLL trial i.e. considered to have a diagnosis of CLL
by another center, as “trial” cases (2,427/11,721) while
all other cases were classified as “primary referral”
(9,294/11,721).
FIG. 2. Simple gating strategy for defining positive and negative internal control populations to assess the relative signal on markers required for
diagnosis according to the consensus criteria. [Color figure can be viewed at wileyonlinelibrary.com]
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The high proportion (7,379/9,294, 79%) of primary
referral cases met the proposed criteria and obtained a
diagnosis of CLL. A clear alternative diagnosis (e.g. man-
tle cell lymphoma) was made in 54% (1,025/1,915) of
primary referral cases that did not meet the proposed
criteria. For primary referrals not meeting the criteria
and not having a clear alternative diagnosis, a final diag-
nosis of CLL was made using the diagnostic unit’s cur-
rent practice in 2.7% of total CD51 LPD cases (n5 251,
28% of cases not meeting the proposed criteria); there
was insufficient material or data on the final diagnosis
was not available in 6.9% of total CD51 LPD cases
(n5 639, 72% of the 890 cases not meeting the pro-
posed criteria) of cases. For primary referral cases, there
was concordance in 97.2% (9,043/9,294, comprising
7,379 diagnosed with CLL, 1,025 diagnosed with
another non-CLL B-LPD and 639 non-diagnostic with
both approaches) using the reproducible criteria com-
pared to each laboratory’s current practice.
The vast majority (2,267/2,427, 93.4%) of trial refer-
rals i.e. cases previously considered to have a diagnosis
of CLL at another center, were confirmed to meet the
proposed criteria by the referral center (classed as true
positive). There were 160 cases that did not meet the
proposed CLL criteria, of which 54/160 had a clear alter-
native diagnosis and 93/160 were considered ineligible
for the trial due to lack of sufficient diagnostic material
or non-specific diagnosis (true negative n5 147/2,427,
6.1%). 13/160 were finally classified as CLL (false nega-
tive) and included in the relevant trial (false negative
n5 13/2,427, 0.5%). Based on cases referred for entry
into a clinical trial and using each center’s current prac-
tice, the proposed criteria would have a negative predic-
tive value of 92% with a positive predictive value, specif-
icity and sensitivity for the diagnosis of CLL of >99%.
Evaluation of a Pilot Study to Assess Reagent
and Instrument Quality
The 13 participants providing retrospective data were
invited to assess the proposed specifications for the six
markers identified as “required” for diagnosis of which
11/13 responded. Using a simple gating strategy (Fig. 2),
participating centers evaluated 10 cases with polyclonal
B-cells. The details and performance characteristics for
the individual markers used in the 11 different centers
are shown in Table 3. Each center used a different
combination of reagents but the performance character-
istics were optimal in 525/600 (88%) for individual
reagents. Only 1/11 centers obtained optimal results
(i.e. the relative signal was above the minimum relative
fluorescence intensity of positive and negative control
populations) for all six markers in all 10 cases. A further
3/11 centers had some borderline signals (defined as 1–
3 cases with results below the relative signal target
value), in most cases likely to reflect the samples rather
than instrument/reagent quality (e.g. two cases with
weak CD23 expression on the polyclonal B-cells at cen-
ter 4). Sub-optimal signals (defined as >3 cases with
results below the relative signal target value) were iden-
tified with respect to an individual marker in 7/11 cen-
ters. In one case, this reflected a limitation of the pro-
posed gating strategy for centers using a multiplex
approach (CD20 at center 3). Several centers had sub-
optimal results for the CD5 reagent, which may indicate
that this marker requires a more stringent specification.
The other sub-optimal results may be due to one or
more of several factors (e.g. clone, fluorochrome, manu-
facturer, equipment, and operating procedure) and do
not necessarily relate to the reagent used. Optimizing
and standardizing each component of the process can
be labor-intensive and should be specifically addressed
in order to improve the overall quality of CLL diagnosis,
even when using the most “basic” markers. The rela-
tively simple global approach developed by ERIC/ESCCA
to assess the CLL diagnostic panel is applicable to a vari-
ety of reagent and instrument suppliers and can easily
identify potential problems or confirm acceptable per-
formance in individual laboratories. In addition, it can
be utilized in the future as the basis for a more homoge-
neous and standardized diagnostic approach in CLL,
allowing cross-center comparison and reproducibility
both in clinical trials as well as daily diagnostic
procedures.
SUMMARY
CLL is one of the most common diagnoses made by
hematology–oncology laboratories. Flow cytometry plays
a central role in diagnosis but differential diagnosis
remains an issue in a small proportion of cases. Due to
the lack of a pathognomonic molecular abnormality in
CLL there is no a gold-standard for its diagnosis. Also,
characteristic immunophenotypic features, such as weak
Table 2
Retrospective Assessment of the Proposed Criteria for Diagnosis of CLL
Not meeting the proposed criteria
Requires MDT or trial-total
CD51 B- specific decision
Total CD51 B-LPD
diagnoses
Meeting the
proposed criteria and
diagnosed with CLL
Other diagnosis,
e.g. Mantle cell
lymphoma
Not CLL or
not specified
Diagnosed
with CLL
Primary referral 9,294 7,379 (79.4%) 1,025 (11%) 639 (6.9%) 251 (2.7%)
Trial 2,427 2,267 (93.4%) 54 (2.2%) 93 (3.8%) 13 (0.5%)
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expression of sIg and CD20, are difficult to define in a
reproducible fashion, thus making it difficult to ensure
consistent diagnosis across laboratories.
This study demonstrates clear consensus on the mini-
mum set of markers required for the diagnosis of CLL:
CD19, CD5, CD20, CD23, Kappa, and Lambda. The
identification of positive and negative control popula-
tions in normal peripheral blood, as well as uniform per-
formance criteria facilitate the evaluation of the
diagnostic quality and a reproducible diagnosis. The
approach piloted in this study provides a comprehensive
evaluation of the components of the diagnostic flow
cytometry process including technical equipment and
specific combinations and concentrations of reagents
allowing a reproducibility and comparability among dif-
ferent laboratories. The results demonstrate that this
goal has still to be consistently achieved, particularly
with respect to the CD5 reagents.
Table 3
Assessment of the Reagents and Instrument Set-up in Different Centers by Evaluating the Relative Signal of Required Diagnostic
Markers on Control Samples
Antigen CD19 CD20 CD5 Kappa Lambda CD23
Relative signal
target value 10 10 30 5 5 5
Center 1 225
(123–479)
HD37 RPE-Cy5
127
(51.9–183)
L27 FITC
56.3b
(16.2–5,892)
DK23 APC
24.4
(12.6–87.6)
Polyclonal FITC
100
(44.8–302)
Polyclonal PE
11
(7.4–17.9)
MHM6 FITC
Center 2 5,462
(4,291-6,393)
LT19 APC
64.8
(36.6–103)
2H7 APE-eF780
41.1a
(17.7–57.2)
L17F12 V450
17.1a
(4.9–37.6)
G20–193 APC-H7
2.9b
(2.1–4.9)
1–155-2 APC
4b
(3.1–6.8)
Tu1 FITC
Center 3 12,126
(85.1–14,264)
J3–119 PE-Cy7
5.4b
(2.5–7.1)
L27 V450
44.2a
(2.8–102)
L17F12
PerCP-Cy5.5
20.2
(7.1–55.5)
Polyclonal PE
35.8
(8.4–116)
Polyclonal FITC
43.2a
(0.8-1,670)
MHM6 FITC
Center 4 17.9a
(5.6–23.5)
SJ25C1
PerCP-Cy5.5
175
(102–306)
L27 FITC
237
(52.8–368)
L17F12 PE
35.6
(12.6–60)
TB28-2 FITC
430
(148–612)
1–155-2 PE
49a
(2.5–223)
EBVCS-5 PE
Center 5 16.5
(11.2–18.8)
SJ25C1
PerCP-Cy5.5
24.6
(16.7–30.2)
L27 APC-H7
42.9a
(15.1–56.7)
L17F12 PE-Cy7
22.6
(10.3–65.1)
G20–193 BV421
17.5
(10.3–24.2) JDC-
12 FITC
18.7
(8.6–31.7)
M-L233 BV421
Center 6 56.8
(32.8–81.9)
J3–119 PE-Cy7
2,812
(398-5,030)
2H7 PacBlue
37.2a
(24.4–105)
L17F12
PerCP-Cy5.5
19.7
(11.4–65.6)
Polyclonal FITC
74.4
(13.6–317)
Polyclonal PE
15.4
(9.7–39.3)
MHM6 FITC
Center 7 106
(89.9–175)
SJ25C1 APC
53.6
(41.2–67.4)
L27 PerCP
26.2b
(17.9–39)
L17F12 FITC
22.1
(6.9–45.1)
TB28-2 FITC
149
(72.2–287)
1–155-2 PE
16.9
(8.6–35)
EBVCS-5 PE
Center 8 217
(130–234)
J3–119 PE-Cy7
82
(58.8–145)
2H7 Pacific Blue
88.6
(51–123)
BL1a APC
25.3
(10.7–80.1)
Polyclonal PE
19.6
(7.4–74.8)
Polyclonal FITC
10.3
(5.8–14.1)
9P25 FITC
Center 9 16.3a
(5.5–130)
J3–119 PE-Cy7
29.9
(18.3–58.7)
B-Ly1 FITC
5.4b
(2.4–45.6)
BL1a PE
12.3a
(4.7–29.7)
Polyclonal FITC
46.6
(6.5–75.5)
Polyclonal PE
19.1
(9.8–48.4)
9P25 FITC
Center10 31.6
(22.6–41.7)
J3–119 ECD
(Coulter)
82.1
(38.4–119)
B9E9 Pacific Blue
16.6b
(3–31.5)
BL1a
APC-AF750
6.1a
(1.7–11.2)
Polyclonal FITC
18
(12.3–37)
Polyclonal PE
9.1
(7.1–13.6)
9P25 APC-AF700
Center 11 142
(20.2–10,558)
SJ25C1 APC
99.5
(46.9–240)
L27 FITC
24.1b
(9.7–45.8)
L17F12 PerCP-
Cy5.5
87.1
(33.3-3,398)
TB28-2 FITC
160
(55.4-2,821)
1–155-2 PE
70.6
(31.3–290)
EBVCS-5 PE
The signal for each marker on the internal positive and negative controls was determined using a simple gating strategy applied
to ten control cases (see Fig. 2). The table shows the median relative signal (range) for the cases above the clone and fluorochrome
(supplier).
aIndicates that the results were sub-optimal in 1–3 of the 10 cases, typically reflecting issues with individual samples rather
than instrument/reagent quality.
bIndicates that the results did not meet the specified criteria in >3/10 cases due to one or more of several factors such as clone,
fluorochrome, manufacturer, equipment, or operating procedures as well as factors related to the evaluation procedure such as a
limitation in the proposed gating strategy with multiplex approaches
(e.g. CD20 at center 3).
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A further component of this project was to identify a
panel of reagents that may improve differential diagno-
sis. The identification of markers that could contribute
to differential diagnosis is confounded not only by the
lack of a diagnostic gold-standard, but also because new
markers are often assessed along with others that may
also contribute to the differential diagnosis. In this
regards, it is recommended that in addition to the mini-
mum panel, reference centers and those involved in
research assess CD43, CD79b, CD81 (required also for
subsequent disease monitoring and MRD assessment), as
well as CD200, CD10, & ROR1 (useful for differential
diagnosis of CLL vs. mantle cell lymphoma, and
germinal-center B-LPD vs. post-germinal center B-LPD,
respectively) (8,22,23). This should provide a stable plat-
form for evaluating the contribution of cellular markers
to the diagnosis and prognosis in CLL.
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